Non-Hodgkin Lymphoma in Adults

We use molecular and genetic tests to diagnose non-Hodgkin lymphoma. This form of cancer arises in the body’s lymphatic system—the network of vessels, nodes, and other organs that drain excess fluid from tissues and help the body fight infections. These tests enable our hematologists, or blood cancer specialists, to create a personalized treatment plan for you. Approaches may include chemotherapy, targeted medications, stem cell transplantation, and radiation therapy. We can also determine whether you may benefit from new therapies being studied in clinical trials.

Clinical Trials and Research Studies

Phase 3

AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Learn More

Phase 1

A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Learn More

Phase 1

A PHASE 1 OPEN-LABEL DOSE FINDING STUDY OF CC-95251 A MONOCLONAL ANTIBODY DIRECTED AGAINST SIRPa ALONE AND IN COMBINATION WITH CETUXIMAB OR RITUXIMAB IN SUBJECTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS

Learn More

Phase 2

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine Rituximab High Dose Cytarabine and Acalabrutinib (BR/CR-A) and 3.) Bendamustine Rituximab and Acalabrutinib (BR-A) in Patients = 70 years old with Untreated Mantle Cell Lymphoma

Learn More